How does the EU encourage pharmaceutical innovation?
Ben Brigou and Jaap Mannaerts of NLO examine the different incentives the EU offers in order to encourage pharmaceutical innovation, including SPCs, regulatory measures and the Bolar exemption
The protection of pharmaceutical products within the European Union is the result of a complex interplay of different mechanisms which all have one thing in common – they are aimed at encouraging pharmaceutical innovation. While not purporting to be exhaustive...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.